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Abstract 
 
 Core-polymerized and boron-conjugated micelles (PM micelles) were prepared by free radical 
copolymerization of a PEG-b-PLA block copolymer bearing an acetal group and a methacryloyl 
group (acetal-PEG-b-PLA-MA), with 1-(4-vinylbenzyl)-closo-carborane (VB-carborane), and the 
utility of these micelles as a tumor-targeted boron delivery system was investigated for boron 
neutron capture therapy (BNCT). Non-polymerized micelles (NPM micelles) that incorporated 
VB-carborane physically showed significant leakage of VB-carborane (ca. 50%) after 12 h 
incubation with 10% fetal bovine serum (FBS) at 37 ºC. On the other hand, no leakage from the PM 
micelles was observed even after 48 h of incubation. To clarify the pharmacokinetics of the micelles, 
125
I (radioisotope)-labeled PM and NPM micelles were administered to colon-26 tumor-bearing 
BALB/c mice. The 
125
I-labeled PM micelles showed prolonged blood circulation (area under the 
concentration curve (AUC): 943.4) than the 
125
I-labeled NPM micelles (AUC: 495.1), whereas 
tumor accumulation was similar for both types of micelles (AUCPM micelle: 249.6, AUCNPM micelle: 
201.1). In contrast, the tumor accumulation of boron species in the PM micelles (AUC: 268.6) was 
7-fold higher than the NPM micelles (AUC: 37.1), determined by ICP-AES. Thermal neutron 
irradiation yielded tumor growth suppression in the tumor-bearing mice treated with the PM 
micelles without reduction in body weight. On the basis of these data, the PM micelles represent a 
promising approach to the creation of boron carrier for BNCT. 
 
*Abstract
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1. Introduction 
 
 Boron neutron capture therapy (BNCT) has attracted much attention as a selective and noninvasive 
type of cancer therapy [1,2]. This therapy is based on the capture reaction of thermal neutrons using 
nonradioactive 
10
B, which produces particles and 7Li nuclei with approximately 2.3 MeV of 
energy. These high linear-energy-transfer (LET) particles dissipate their energy before traveling 
across the diameter of cells (5-9 m) within tissues, resulting in cytotoxic effects. Two types of 
10
B-compunds, sodium borocaptate (BSH) and L-4-dihydroxyboronylphenylalanine (BPA), have 
been utilized for clinical trials. However, due to the rapid clearance of these compounds from the 
bloodstream (half-life of blood circulation time of BSH, BPA: t1/2 < 1 h) [3], a high dose of 
10
B-compounds is generally required to allow a sufficient concentration of 
10
B atoms to accumulate 
in tumor tissues (BSH: 41 mg 
10
B/kg, BPA: 58 mg 
10
B/kg) [4]. Meanwhile, with BNCT, it is 
theoretically possible to kill tumor cells without damage to normal cells if 
10
B atoms can be 
selectively accumulated in tumor tissues (15–30 ppm of 10B atoms per gram of tumor tissue). 
Therefore, the therapeutic value of cancer BNCT under in vivo conditions is largely dependent on 
the development of effective boron carrier systems that can achieve modulated disposition in the 
body through the intravenous route as well as facilitate accumulation in tumor tissues. Maeda and 
Matsumura reported that large-molecular-weight compounds, including nanoparticles tend to 
accumulate in tumors due to the presence of leaky neovascular walls and an immature lymphatic 
system in tumors (a phenomenon called the enhanced permeability and retention (EPR) effect) [5,6]. 
The high levels of nanoparticle accumulation can be achieved via the EPR effect if the nanoparticle 
has a tendency for prolonged circulation within the bloodstream, since the EPR effect builds up 
*Manuscript
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gradually over several days. Thus, prolonged circulation of nanoparticles, for at least several days, 
in the bloodstream is a preferable feature in development of cancer therapeutics. To improve the 
therapeutic effect of cancer BNCT, a variety of boron-delivery systems, such as BSH-encapsulated 
PEG-modified liposomes, have been developed, and some of these can allow accumulation to 
substantially higher levels in tumor tissues than that achieved with free BSH [7-9]. However, the 
therapeutic efficacy of BSH-encapsulated liposomes is still controversial due to the leakage of the 
encapsulated BSH from the liposome into the bloodstream [10]. An alternative approach 
represented by the 
10
B-compound-conjugated liposomes fabricated by covalently linking a lipid 
(hydrophobic group) with a 
10
B-compound (hydrophilic group) to suppress the leakage of the 
10
B-compound into the bloodstream [11,23]. However, the synthesis of nido-carborane required 
complicated preparation steps. Additionally, serious acute toxicity was observed in vivo because of 
the cytotoxicity of nido-carborane [23]. 
We have studied nano-sized polymeric micelles constructed from AB-type amphiphilic block 
copolymers as drug carrier and reported the selective accumulation into tumor tissues through the 
EPR effect [12]. However, one of the disadvantages of utilizing polymeric micelles as the drug 
carrier was leakage of the drug incorporated in the micelles during blood circulation [13-15]. 
Therefore, we attempted to prepare polymeric micelles by conjugating the boron compounds 
through covalent bonds, since release of the incorporated drugs from nanoparticles is not required 
for BNCT. Recently, we reported the development of a new class of boron delivery systems based 
on core cross-linked and boron-conjugated micelles prepared by radical polymerization of 
poly(ethylene glycol)-block-poly(lactide) copolymer (PEG-b-PLA), which bears an acetal group at 
the PEG end and a methacryloyl group at the biodegradable PLA end (acetal-PEG-b-PLA-MA) and 
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a polymerizable carborane bearing two vinylbenzyl groups (1,2-bis(4-vinylbenzyl)-closo-carborane) 
as the cross-linker [16]. Indeed, the obtained core cross-linked and boron-conjugated micelles 
showed no leakage of boron compounds from the micelles under physiological conditions even in 
the presence of fetal bovine serum (FBS) at 37 ºC, while significant leakage (80%) of boron 
compounds was observed from the non-cross-linked micelles, which incorporate the boron 
compounds by physical entrapment. The boron concentrations in both blood (13.5%ID/g) and tumor 
tissues (5.4%ID/g) of tumor-bearing mice injected with the core cross-linked micelles were 
significantly higher at 24 h after the injection than in the mice injected with the non-cross-linked 
micelles (blood: 1.8%ID/g, tumor: 1.4%ID/g). However, the loading content of the carborane in the 
micelles was insufficient (ca. 1.0 wt%), probably due to low compatibility of the carborane with the 
micelle core. From calculations made using the pharmacokinetic data, a huge dose (2,000–3,000 
mg/kg) would be required to attain a therapeutically effective boron concentration in tumor tissue 
for BNCT (15–30 ppm of 10B atoms per gram of tumor tissues), if one were to use the core 
cross-linked micelle. For this reason, it was difficult to utilize the core cross-linked and 
boron-conjugated micelles as boron carriers for in vivo BNCT.  
In this study, we prepared and characterized core-polymerized (but not cross-linked) and 
boron-conjugated micelles (PM micelles) with high loading content by performing free radical 
copolymerization of the core of the acetal-PEG-b-PLA-MA micelles with polymerizable 
(mono-functional) 1-(4-vinylbenzyl)-closo-carborane (VB-carborane) as a comonomer (Figure 1). 
Note that no cross-linking agent was used in the core-polymerization system. The VB-carborane 
bearing a vinylbenzyl group and a CH group, was synthesized to increase the loading contents of 
the boron compounds in the core. Because the CH group of the carborane has been reported to 
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exhibit an acidic nature, the loading occurs when the CH group of carborane and carbonyl group 
(C=O) of the PLA segment interact to form a C-H…O=C hydrogen bond [17]. PM micelles with 
high loading content of boron compounds are expected to suppress the leakage of the boron 
compounds into the bloodstream due to the existence of the covalent bonds between the boron 
compounds and the PLA core, leading to prolonged blood circulation time and enhanced tumor 
accumulation. Additionally, the PM micelles are expected to excrete easily from major organs via 
biodegradation of the PLA core. The PM micelles are thus expected to exert significant therapeutic 
effects when used with thermal neutron irradiation in tumor-bearing mice because of the high 
concentration of boron atoms in the tumor tissues, which can be attributed to the high stability of 
the micelles in the bloodstream. We believe that the use of PM micelles composed of 
acetal-PEG-b-PLA-MA and VB-carborane represents a promising approach to the creation of boron 
carriers for cancer BNCT. 
 
2. Materials and methods 
 
2.1. Materials 
 
Azobisisobutironitrile (AIBN; Wako Pure Chemical Industries, Ltd., Osaka, Japan) was purified 
by recrystallization from methanol and dried in vacuo. N,N-Dimethylacetamide (DMAc; Kanto 
Chemicals Co., Ltd., Tokyo, Japan), o-carborane (Wako Pure Chemical Industries), 
10
B-enriched 
o-carborane (Katchem spol. s.r.o., Ltd., Prague, Czech), 
10
B-enriched BSH (Katchem spol. s.r.o., 
Ltd.) and poly(ethylene glycol) bearing a methoxy group at the  end and a hydroxyl group at the  
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end (MeO-PEG-OH) (Fluka Chemie GmbH Co, Germany) were used as received. The molecular 
weight of the MeO-PEG-OH was 5,000 g/mol. Water was purified using the Milli-Q system 
(Millipore). Dynamic light scattering measurements were carried out in phosphate-buffered saline 
(PBS) at 37 °C using a Zetasizer Nano-ZS instrument (Malvern, UK) equipped with a 4.0 mW 
He–Ne laser (633 nm). Zeta potential measurement of the micelles was performed at 37 ºC in 5 mM 
phosphate buffer solution at pH 7.4 using a Zetasizer Nano-ZS. 
1
H-NMR spectra were obtained in 
chloroform-d at 25 ºC with a JEOL EX270 spectrometer (JEOL, Japan). Chemical shifts were 
reported in ppm relative to CHCl3 ( 7.26 ppm). The concentration of boron atoms was 
determined by inductively coupled plasma atomic emission spectroscopy (ICP-AES) using an 
ICAP-575 emission spectrometer (Nippon Jarrell-Ash, Japan). Fourier transform infrared 
spectroscopy (FT-IR) measurements were performed using an FT/IR-300 spectrometer (JASCO, 
Tokyo, Japan). FT-IR spectra were collected by the KBr pellet method at a resolution of 4 cm
-1
 with 
128 scans. 1-(4-Vinylbenzyl)-closo-carborane (VB-carborane) was synthesized by a previously 
reported procedure [18]. The data obtained by elemental analysis, ICP-AES measurement, MS 
measurement, and 
1
H-NMR measurement of VB-carborane are summarized in Supplementary data. 
Acetal-PEG-b-PLA-MA was synthesized as per the method described in our previous report [19], 
and the molecular weight of the PEG segment and the PLA segment of the block copolymer were 
estimated to be 5,600 and 5,100 g/mol, respectively. The detailed characterization data of 
acetal-PEG-b-PLA-MA are summarized in Supplementary data. Acetal-PEG-b-PLA-MA micelles 
were also prepared by the method described in our previous report [19]. The average diameter and 
size distribution (= 2/
2
) of the acetal-PEG-b-PLA-MA micelles were found to be 38.4 nm and 
0.027, respectively, as determined by DLS measurements. Cytotoxicity of the samples was 
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evaluated by WST assay as described in Supplementary data. 
 
2.2. Preparation of PM and NPM micelles 
 
The core-polymerized and boron-conjugated micelles (PM micelles) were prepared as described 
previously [16,19]. A solution of VB-carborane (9.2 mg) and AIBN (0.3 mg) in chloroform (1.0 
mL) was added dropwise to 10 mL of a stirred aqueous solution of acetal-PEG-b-PLA-MA micelles 
(2.0 mg/mL) to form an o/w emulsion. The o/w emulsion was kept for 1 h, and the solution was 
exposed to air at 25°C for 3 h to evaporate the chloroform, after which the resulting micelle solution 
was purged with nitrogen gas for 20 min to remove the remaining chloroform and dissolved oxygen 
completely. To prepare the PM micelles, polymerization was carried out at 60 °C for 24 h. 
Purification was carried out by repeated ultrafiltration using a membrane with a molecular weight 
cut-off of 100,000 (VIVASPIN 4, Sartorius Stedim Biotech, Germany). For comparison, 
non-polymerized micelles (NPM micelles) encapsulating VB-carborane were prepared by the same 
procedure as that for PM micelles, without the addition of AIBN and heating. To determine the 
average diameter and size distribution of the micelles, DLS measurements were carried out in PBS 
at 37°C. Zeta potential measurement of the micelles was performed at 37ºC in 5 mM phosphate 
buffer solution at pH 7.4. To check whether the VB-carborane was covalently conjugated the core 
of the micelles, 
1
H-NMR measurements of the lyophilized PM and NPM micelles were carried out 
in CDCl3 at 25 ºC. The loading content and efficiency of the boron atoms in the micelles were 
determined using ICP-AES. To clarify the interaction between the VB-carborane and the 
acetal-PEG-b-PLA-MA, FT-IR measurements of the VB-carborane, the acetal-PEG-b-PLA-MA, the 
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MeO-PEG-OH and the mixture of the VB-carborane and the acetal-PEG-b-PLA-MA were 
performed by the KBr pellet method. Degradation of the NPM and PM micelles under the 
physiological conditions was confirmed by size exclusion chromatography (SEC) analysis using a 
JASCO HPLC system (JASCO, Tokyo, Japan) equipped with a refractive index (RI) detector 
(RI-2031) and a Superose 6 10/300 GL column (GE Healthcare, USA) with 10 mM phosphate 
buffered saline (pH 7.4, containing 150 mM NaCl) at a flow rate of 0.50 mL/min at 40 ºC. The PM 
or NPM micelles solution (1.0 mg/mL) in 10 mM PBS was incubated at 37 ºC. At a defined time 
interval, 50 L aliquots were subjected to SEC system after filtration through 0.45 m filter. 
 
2.3. Leakage of VB-carborane from PM and NPM micelles 
 
The leakage of VB-carborane from the PM and NPM micelles was evaluated at 0.23 mg/mL of 
micelles, well above the critical association concentration of both the micelles (ca. 2–3 g/mL), 
under physiological conditions and in the presence of 10% FBS. Briefly, a solution of the PM and 
NPM micelles (1.0 mg/mL, 3 mL) with 10% FBS was poured into dialysis bags (MWCO: 100,000), 
and each bag was immersed in 10 mL of physiological saline with 10% FBS at 37 °C. At a definite 
time interval, 0.5 mL of the solution outside the dialysis bag was sampled, and then the solutions 
were diluted to 20 mL with distilled water. After filtering through 0.45m filters (Millipore), 
ICP-AES measurement of the solution was carried out to determine the amount of VB-carborane 
released from each micelle based on the concentration of boron atoms, which was determined using 
a calibration curve based on boric acid (ultratrace analysis grade, Aldrich Chemical Co. Ltd., 
Milwaukee, WI). 
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2.4. Pharmacokinetics of 
125
I-labeled PM and NPM micelles 
 
 All procedures involving animal care were approved by the Animal Ethics Committee of the 
University of Tsukuba, and were conducted according to the Guidelines for Animal 
Experimentation of the University of Tsukuba. To characterize the pharmacokinetics of the micelles, 
the preparation of the 
125
I(radioisotope)-labeled PM and NPM micelles was performed according to 
our previous report [16,20]. As described in the previous report, using the acetal group at the end of 
the PEG chain, a tyrosine residue was introduced as a site of radiolabeling onto the PM or NPM 
micelles. The detailed procedure is described in Supplementary data. The biodistribution of the 
125
I-labeled PM micelles and 
125
I-labeled NPM micelles was evaluated in tumor-bearing, 
5-week-old male BALB/c mice (n = 3, 20-25 g, Charles River, Japan). Tumors were induced in the 
mice by subcutaneous injection of colon-26 cells (1.0 × 10
6
 cells/mouse) into the right femur. When 
the volume of the tumor reached 100 mm
3
, the 
125
I-labeled PM micelles or 
125
I-labeled NPM 
micelles were administered to the tumor-bearing mice by intravenous injection at a dose of 0.80 mg 
boron atoms per kg body weight. Blood, liver, spleen, kidney and tumor samples were collected, 
using sodium pentobarbital (40 mg/kg) as an anesthetic, at defined time periods after injection of 
the micelles. The radioactivity and the weight of the collected samples were measured by a 
-counter (Aloka, Japan) and a balance, respectively. 
 
2.5. Pharmacokinetics of boron species in the PM and NPM micelles 
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The pharmacokinetics of the boron species (VB-carborane) in the PM and NPM micelles were 
evaluated in tumor-bearing 5-week-old-male BALB/c mice (n = 3) on the basis of the concentration 
of boron atoms determined using ICP-AES. As a comparison, the pharmacokinetic of 
10
B-enriched 
BSH, which is clinically utilized, was also evaluated. The PM micelles, NPM micelles or BSH 
solution were administered to the tumor-bearing mice by intravenous injection at a dose of 0.80 mg 
boron atoms per kg body weight. Blood, liver, spleen, kidney and tumor samples were collected at 
defined time periods after the injection under anesthesia with pentobarbital sodium (40 mg/kg) and 
weighted. The freeze-dried tissues were dissolved with 1 mL of HNO3 (ultratrace analysis grade, 
Wako, Japan) and 0.5 mL of hydrogen peroxide solution (ultratrace analysis grade, Kanto 
Chemicals, Japan) at 60 ºC for 3 h. The dissolved samples were then diluted with distilled water. 
After filtering through a 0.45 m filter, the concentration of boron atoms in the tissues was 
measured using ICP-AES. Long-term tissue distribution of boron species in the PM and NPM 
micelles was also examined in normal 5-week-old-male BALB/c mice. The PM and NPM micelles 
were administered to the mice by intravenous injection at a dose of 0.80 mg boron atoms per kg 
body weight, and the concentration of boron atoms in each tissue was measured using the procedure 
described above. 
 
2.6. BNCT for tumor-bearing mice 
 
Neutron irradiation was carried out in the Japan Research Reactor No. 4 (JRR4) of Japan Atomic 
Energy Agency and Kyoto University Research Reactor (KUR) of Kyoto University Research 
Reactor Institute. 
10
B-enriched PM and NPM micelles were prepared from 
10
B-enriched 
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VB-carborane and acetal-PEG-b-PLA-MA by the same procedure described above. The 
10
B-enriched PM and NPM micelle solutions was injected into colon-26 tumor bearing mice (n = 5) 
via the tail vein at a dose of 15.6 mg 
10
B/kg 24 h before irradiation. For comparison, 
10
B-enriched 
BSH solution was injected 1 h before irradiation via the tail vein at a dose of 30.0 mg 
10
B/kg. The 
mice were anesthetized with pentobarbital sodium (40 mg/kg) and placed in an acrylic mouse holder. 
They were then irradiated in the JRR4 and KUR at a rate of 1.6–1.8 × 1012 neutrons/cm2. The 
effects of BNCT were evaluated in terms of the tumor size, which was estimated by using the 
following equation: V = (a) × (b)
2 
/ 2, where (a) and (b) are major and minor axes of the tumor 
measured by a caliper, respectively. Body weight was measured as an indicator of systemic toxicity. 
 
3. Results and discussions 
 
3.1. Preparation and characterization of PM and NPM micelles 
 
The acetal-PEG-b-PLA-MA was synthesized as described in our previous paper [19], and the 
molecular weights of the PEG and PLA segments of the block copolymer were estimated to be 
5,600 and 5,100 g/mol, respectively. The detailed characterization data of the 
acetal-PEG-b-PLA-MA are summarized in Supplementary data. The VB-carborane was synthesized 
using a previously reported procedure [18] and is described in detail in Supplementary data. To 
prepare the acetal-PEG-b-PLA-MA micelles, the dialysis method was employed as described 
previously [19]. The average diameter of the acetal-PEG-b-PLA-MA micelles was 38.4 nm with a 
narrow size distribution (μ2/Γ
2
 = 0.027), as determined by DLS measurement (Figure S4). To 
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prepare the NPM micelles, the VB-carborane was encapsulated into acetal-PEG-b-PLA-MA 
micelles by means of the solvent evaporation method. The average diameter of the VB-carborane 
encapsulating acetal-PEG-b-PLA-MA micelles (NPM micelles) increased from 38.4 nm to 60.2 nm 
with a narrow size distribution (μ2/Γ
2
 = 0.119), as shown in Figure S4. This is probably due to the 
formation of a loosely associated PLA core as a result of the swelling of the hydrophobic PLA core, 
which occurs upon the addition of chloroform, as previously reported [19]. To prepare the PM 
micelles, both VB-carborane and AIBN were encapsulated into acetal-PEG-b-PLA-MA micelles by 
means of the solvent evaporation method, and the polymerization of the core was carried out at 
60ºC for 24 h. The characteristics of the PM and NPM micelles are summarized in Table 1. The 
average diameter (67.3 nm, μ2/Γ
2
 = 0.113) and zeta-potential (-0.32 ± 0.99 mV) of the PM micelles 
was almost similar to that of the NPM micelles (60.2 nm, μ2/Γ
2
 = 0.119, zeta-potential: -0.15 ± 0.05 
mV), suggesting that the core polymerization process does not influence the size distribution and 
the zeta-potential of the micelles. To confirm that the VB-carborane was covalently linked with the 
end of the PLA chain, 
1
H-NMR measurements of the lyophilized NPM and PM micelles were 
carried out in CDCl3, which is a good solvent for both acetal-PEG-b-PLA-MA and VB-carborane 
(Figure S5). In the spectrum obtained for the NPM micelles, peaks at 5.60 and 6.20 ppm were 
observed, which can be attributed to the methacryloyl group at the end of PLA chain, and peaks for 
the vinyl protons of VB-carborane were observed at 5.70 ppm. These data indicate that both 
acetal-PEG-b-PLA-MA and VB-carborane were dissolved in CDCl3. On the other hand, the peaks 
attributed to the methacryloyl and vinyl groups were reduced by more than 99 % in the spectrum 
obtained for the PM micelles, suggesting that the copolymerization of the acetal-PEG-b-PLA-MA 
and VB-carborane proceeded successfully. The loading content of VB-carborane in the NPM and 
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PM micelles was determined to be 8.5 wt% (loading efficiency: 23.5 %) and 7.7 wt% (loading 
efficiency: 21.5 %), respectively. The loading content of both micelles was comparable, indicating 
that leakage of VB-carborane from the micelles did not occur during the polymerization process. It 
is of note that the loading content of VB-carborane in the acetal-PEG-b-PLA-MA micelles (ca. 1.0 
wt%) increased remarkably in comparison with that in polymerizable carborane bearing two 
vinylbenzyl groups (1,2-bis(4-vinylbenzyl)-closo-carborane) [16]. This increment might be caused 
by the enhancement of the compatibility of the VB-carborane with the PLA core of the micelles due 
to the existence of the hydrogen bonds between the CH group of the VB-carborane and the O atom 
of the carbonyl group (C=O) in the PLA segments. To clarify the interaction between the 
VB-carborane and the acetal-PEG-b-PLA-MA, FT-IR measurements of the VB-carborane, the 
acetal-PEG-b-PLA-MA, the MeO-PEG-OH and the mixture of the VB-carborane and the 
acetal-PEG-b-PLA-MA were performed by the KBr pellet method. The VB-carborane spectrum 
shows the characteristic peaks of VB-carborane at 2578 cm
-1
 ((B-H)) and 3070 cm-1 ((C-H)) 
(Figures 2(A)(a) and 2(B)(a)). The peak of the CH group of the VB-carborane was also observed at 
the same wavenumber (3071 cm
-1
) in the spectrum of the mixture of the MeO-PEG-OH and the 
VB-carborane (Figure 2(A)(c)). This indicates that there might be no interaction between the CH 
group of the VB-carborane and PEG chains. On the other hand, the peak of the CH group of the 
VB-carborane was shifted to 3057 cm
-1
 in the spectrum of the mixture of the 
acetal-PEG-b-PLA-MA and the VB-carborane (Figure 2(B)(c)). This result strongly indicates the 
existence of the hydrogen bonds between the CH group of the VB-carborane and the O atom of the 
carbonyl group (C=O) in the PLA segments, because shifting of the peak of the CH group of 
carboranes in the presence of the hydrogen bond of the C-H
…
O=C has been reported previously 
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[21]. From these results, we concluded that the interaction between carborane and PLA chain via 
hydrogen bonds might be one of the reasons for the higher loading content of the carborane. 
Degradation of the NPM and PM micelles were analyzed using a SEC system equipped with a RI 
detector and a Superose 6 10/300 GL column. As shown in Figures S6(a) and (b), the peaks 
attributed to the NPM and PM micelles were observed by RI detection at 16 min in the region of the 
exclusion limit (Mn > 300,000) at 0 day after incubation. After several days incubation, the peaks 
were appeared at 23 min (Mn = ca. 5,400) attributed to free PEG and the micellar peaks decreased in 
both charts of the NPM and PM micelles dependent the incubation days. Consequently, both the 
NPM and PM micellar peaks were disappeared completely after 19 and 25 days incubation, 
respectively. These results strongly indicate that the PM micelles were able to be degraded via 
biodegradation under the physiological conditions similarly the NPM micelles even though the core 
of the micelles was polymerized. 
It has been reported that certain types of hydrophobic compounds incorporated in polymeric 
micelles by physical entrapment are leaked rapidly after they are administered by intravenous 
injection due to the interaction, and this rapid leakage occurs between the micelles and some blood 
components [13-15]. The leakage of the boron compounds, which are encapsulated in the micelles, 
is potentially toxic to the normal tissues after the irradiation of the thermal neutrons in BNCT. In 
our previous report, the leakage of polymerizable carborane bearing two vinylbenzyl groups 
(1,2-bis(4-vinylbenzyl)-closo-carborane) from the non cross-linked micelles occurred immediately 
under physiological conditions in the presence of 10 % FBS, whereas the cross-linked micelles 
showed complete suppression of carborane leakage under the same conditions, which can be 
attributed to the covalent bonds between the boron compounds and the PLA segments in the 
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micellar core [16]. In this study, the VB-carborane bearing a vinylbenzyl group and a CH group was 
loaded in the micelles. In order to confirm the stability of the PM and the NPM micelles under 
physiological conditions, the leakage of VB-carborane from both micelles was evaluated by dialysis 
at 37 ºC in PBS with 10 % FBS, as shown in Figure 3. The amounts of leaked VB-carborane from 
the micelles were determined by ICP-AES, and the results were based on the concentration of boron 
atoms in the solution of the outside of dialysis bags. Significant amounts (ca. 50%) of 
VB-carborane had leaked from the NPM micelles after 12 h. This means that the stability of the 
VB-carborane physically entrapped in the acetal-PEG-b-PLA-MA micelles was insufficient under 
physiological conditions in the presence of serum proteins, even though there were interactions 
between VB-carborane and the PLA core. In sharp contrast, the PM micelles showed no leakage of 
the VB-carborane even after 48 h, likely due to the existence of covalent bonds between 
VB-carborane and the PLA core. From these facts, we conclude that covalent conjugation, rather 
than physical entrapment, is required for in vivo stabilization in the case of VB-carborane. The 
cytotoxicity of the PM micelles, NPM micelles, and VB-carborane against colon-26 cells was 
evaluated in the presence of 10% FBS in the cell culture medium as shown in Figure S8. Note that 
the PM micelles showed no toxicity even at high concentration ([B] = 10 mM). In contrast, 50 % 
inhibitory concentration (IC50) values of the NPM micelles and VB-carborane were 4.3 mM and 1.4 
mM, respectively. Moreover, the cytotoxicity of the VB-carborane is lower than the nido-carborane 
derivative (IC50 = 0.5 mM) [24] which has been used in the 
10
B-compound-conjugated liposomes 
[11,23]. Notably that the cytotoxicity of the PM micelles (IC50 = not determined) was significantly 
lower than that of the NPM micelles (IC50 = 4.3 mM). These results indicate that the leakage of the 
VB-carborane from the NPM micelles occurred in the presence of 10% FBS, leading to the 
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cytotoxicity caused by the free VB-carborane. In sharp contrast, the leakage of VB-carborane from 
the PM micelles was suppressed even in the presence of 10% FBS because the VB-carborane was 
conjugated with the core of micelles through the covalent bonds. It can be concluded that the PM 
micelle system is utilized for BNCT from the standpoint of the cytotoxicity. It is important to note 
that the present synthetic method is simple modification of a well-known emulsion polymerization 
technique. Thus, large scale production with reproducible manner of 
10
B-enriched PM micelle is 
strongly anticipated for clinical trials in future. 
 
3.3. Pharmacokinetics studies of the micelles and boron species 
 
In a recent study, we found that compared to the non cross-linked micelles physically 
encapsulating the carboranes, the core cross-linked and boron-conjugated micelles prepared by 
polymerization of acetal-PEG-b-PLA-MA with polymerizable carborane bearing two vinylbenzyl 
groups (1,2-bis(4-vinylbenzyl)-closo-carborane) showed higher tumor accumulation of boron 
species at 24 h after injection, although the tumor accumulation of both micelles at 24 h after 
injection was similar [16]. This means that the distribution of boron species (carboranes) in the 
cross-linked and non cross-linked micelles was different, perhaps due to the leakage of the 
carborane into the bloodstream. In this study, we performed pharmacokinetic measurements, to 
clarify the distribution of both the micelles and the boron species after injection. 
The micelle and boron concentrations in various tissues, such as liver, kidney, spleen, tumor, and 
blood, were measured at defined time periods after their injection into tumor-bearing mice. For the 
pharmacokinetics study of the micelles, a radioisotope (
125
I) was introduced at the end of the 
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PEG-chain after L-tyrosine installation, as described in our previous report [16,20]. The acetal 
groups at the end of PEG chains on the micelles were de-protected through acid treatment to 
convert the reactive aldehyde groups, and this was followed by the addition of L-tyrosine hydrazide 
and sodium cyanoborohydride as a reductant. 
125
I-labeling was performed using the conventional 
chloramine T method (Supplementary data, Figure S7). The radioactivity level of the 
125
I-labeled 
PM and NPM micelles in each of tissues and blood were expressed as a percentage of the injected 
dose per gram tissue (%ID/g) at specified times after intravenous injection in tumor-bearing mice, 
as shown in Figures 4 and S9. The area under concentration curve (AUC) values in each tissue at 
48 h after injection, and the AUC ratios (PM/NPM) are summarized in Table 2. Note that 9.5%ID/g 
of 
125
I-labeled PM micelles remained in the bloodstream after 48 h, whereas only 5.6%ID/g of 
125
I-labeled NPM micelles remained 48 h after injection (Figure 4(a)). The AUC value of the 
125
I-labeled PM micelles in blood (943.4) was higher than that of the 
125
I-labeled NPM micelles 
(495.1) (AUC ratio: 1.91). Additionally, the 
125
I-labeled NPM micelles (8.2%ID/g) showed higher 
radioactivity levels than the 
125
I-labeled PM micelles (3.2%ID/g) in the kidney after 1 h (Figure 
S9(c)), indicating that a portion of the NPM disintegrated in the bloodstream and was excreted via 
the renal pathway. In contrast, the PM micelles showed extremely high stability in the bloodstream 
due to the covalent conjugation of the PLA segment in the micelles with VB-carborane. The longer 
circulation times of these micelles are suitable for accumulation in tumor regions via the EPR effect. 
The AUC values of the 
125
I-labeled PM micelles in both liver (619.1) and spleen (581.0) were 
slightly higher than those of the 
125
I-labeled NPM micelles (liver: 350.7, spleen: 409.6). These 
increments are probably due to the prolongation of the blood circulation time of the 
125
I-labeled PM 
micelles. In contrast, there were no significant differences in the radioactivity levels in the tumor 
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(AUC ratio (PM/NPM): 1.24) between the 
125
I-labeled PM micelles and the 
125
I-labeled NPM 
micelles (Figure 4(b)). These results mean that the effects of micelle core-polymerization on the 
pharmacokinetics were similar to those of micelle core-cross linking, consistent with our previous 
report [16]. 
In order to confirm the pharmacokinetics of the boron species in the tumor-bearing mice after 
injection of the PM micelles, the NPM micelles and BSH, the concentration of boron atoms in 
tissues was evaluated using ICP-AES. Figures 5 and S10 show the distribution of boron species in 
the tumor-bearing mice after the injection of the PM micelles, the NPM micelles and free BSH. The 
concentrations of the boron atoms in each of the tissues and blood at specific times after the 
intravenous injection are expressed as %ID/g, as determined by ICP-AES. The AUC values of 
boron species in each of the tissues and blood after injection and the corresponding AUC ratios 
(PM/NPM) are summarized in Table 3. The boron species of both NPM micelles (1.1%ID/g) and 
PM micelles (4.6%ID/g) remained in the bloodstream even 48 h after the injection, whereas over 
99% of the injected dose of free BSH was immediately eliminated from the bloodstream by renal 
clearance, because the amounts of BSH accumulated in the kidney 1 h after the injection 
(22.8%ID/g) were apparently higher than those of both the NPM (12.6 %ID/g) and the PM micelles 
(5.1%ID/g) (Figures 5(a) and S10(c)). The post-injection AUC value of PM micelles in blood 
(916.0) was 2.8-fold higher than that of the NPM micelles (330.4). These data indicate that the 
blood circulation time of boron species in the PM micelles was prolonged, likely due to the covalent 
conjugation of VB-carborane to the micelle core matrix. It has also been shown that a large amount 
of VB-carborane is leaked from the NPM micelles into the bloodstream due to the interaction with 
the serum proteins. The distribution of the boron species of the NPM micelles in kidney at 1 h after 
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injection (12.6%ID/g) was 2.5-fold higher than that of the PM micelles (5.1%ID/g) (Figure S10(c)), 
and higher than those of the 
125
I-labeled NPM micelles (8.2%ID/g). These data suggest that the 
VB-carborane was leaked from the NPM micelles easily, and eliminated from the bloodstream more 
readily than the micelles (polymers) by renal clearance, due to the low-molecular weight of NPM 
micelles. Figure 5(b) shows the tumor accumulation amounts of boron species in the PM micelles, 
the NPM micelles and free BSH. The accumulation level of boron species in the tumor tissues of 
the mice treated with the PM micelles was 5.7%ID/g at 48 h after the injection, whereas those of the 
NPM micelles at 48 h and free BSH at 1 h after the injection were only 0.7%ID/g and 1.6%ID/g, 
respectively. Note that the AUC ratio (PM/NPM) of the boron species of the micelles in tumor 
tissues (AUC ratio: 7.29) was remarkably higher than that of the 
125
I-labeled micelles (AUC ratio: 
1.24) (Tables 2 and 3). It should be noted that the PM micelles were remained in the tumor tissues 
for 48 h after the injection by EPR effect, whereas BSH was excreted from the tumor rapidly. This 
indicates that there is enough time to precisely determine the 10B concentration by several 
techniques after injection of the PM micelles because the 
10
B concentration in tumor is constant for 
several days, suggesting that the effective radiation of the thermal neutrons is permitted by utilizing 
the PM micelles. Using the obtained data, tumor-to-blood (T/B) ratios of the boron concentration in 
the tumor-bearing mice were determined as a function of time as shown in Figures 6. Although 
no remarkable difference between the T/B ratios of the micelles, viz., the PM and NPM micelles 
was observed as shown in Figure 6(a), a significant difference in T/B ratio was observed in terms 
of the boron species. For example, the T/B ratio of boron species increased gradually up to 48 h 
when the PM micelle was used as the carrier, while it did not increase with the NPM micelle 
(Figure 6(b)). These data strongly suggest that in the case of PM micelles, the VB-carborane and 
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the micelles concomitantly accumulated in tumor tissues because of the covalent conjugation of the 
VB-carborane with the block copolymer. On the other hand, the VB-carborane in the NPM micelles 
was leaked easily during circulation in the bloodstream after the injection, leading to lower 
accumulation of boron species than that of the micelles in tumor tissues. These results strongly 
indicate that the PM micelles were sutable boron carriers for tumor regions due to the high stability 
in the bloodstream. Further improvement in tumor accumulation is now under investigation and will 
be publish elsewhere. 
We have demonstrated the high accumulation tendency of the boron-conjugated PM micelles to 
tumor regions by performing covalent conjugation of VB-carborane to the core of the micelles. 
Because the covalent conjugation of the core of the micelles via VB-carborane increases the 
molecular weight of the matrix, it may also alter the excretion of the PM micelles from the body. 
Long-term accumulation of certain types of nanoparticles in the body often causes unexpected 
toxicity [22]. Long-term distribution of boron species in major tissues (blood, liver, spleen, and 
kidney) after intravenous injection of the PM and NPM micelles was investigated up to two weeks 
using normal mice. As can be seen in Figure 7, both boron species in the PM and NPM micelles 
were almost completely eliminated from major organs at 7 d after injection, which was determined 
by the ICP-AES measurements. Even though VB-carborane was conjugated covalently in the core 
of the PM micelles, almost complete excretion of the boron species was confirmed, which was 
probably caused by hydrolysis of the ester linkage in the PLA segment. These results strongly 
suggest that the PM micelles are useful not only for enhancing their selective accumulation in tumor 
tissues, but also for promoting the safety of the micelles. 
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3.4. BNCT for tumor-bearing mice 
 
The effects of 
10
B-enriched PM micelles, NPM micelles and BSH on tumor growth suppression 
were examined with thermal neutron irradiation. The 
10
B-enriched PM and NPM micelles were 
prepared from 
10
B-enriched VB-carborane by means of the same procedure as for the PM, NPM 
micelles described above. The average diameter of the 
10
B-enriched PM micelles (61.0 nm, 2/
2
 = 
0.120) and 
10
B-enriched NPM micelles (60.6 nm, 2/
2
 = 0.101) were similar to those of the PM 
micelles (67.3 nm, μ2/Γ
2
 = 0.113) and the NPM micelles (60.2 nm, μ2/Γ
2
 = 0.119) prepared using 
naturally abundant VB-carborane. The 
10
B atoms concentrations in each tissue (blood, liver, spleen, 
kidney, and tumor) of the tumor-bearing mice at 24 h after injecting the 
10
B-enriched PM or NPM 
micelles were determined using ICP-AES (Figure 8). The 
10
B atoms concentration at 24 h after 
injection of the 
10
B-enriched PM micelles in the tumor (14.0 ppm) was about 4.2-fold higher than 
that of the 
10
B-enriched NPM micelles (3.3 ppm), suggesting that the high colloidal stability of 
10
B-enriched PM micelles in the blood stream increased its accumulation in the tumor region via the 
EPR effect. Since the highest accumulation of boron species in tumor tissues was observed at 1 h 
after injecting BSH as described above (Figure 5(b)), the 
10
B atoms concentration in each tissue 
was evaluated at 1 h after injecting BSH (Figure 8). The result shows that the 
10
B atoms 
concentration in the tumor at 1 h after injecting BSH was reached 12.3 ppm. From the obtained data 
on PM, NPM micelles and BSH, it is indicated that the sufficient 
10
B atoms concentration was 
achieved after injecting the 
10
B-enriched PM micelles even at a half dose of BSH (
10
B-enriched PM 
micelles: 15.6 
10
B mg/kg, BSH: 30.0 
10
B mg/kg). As stated above, the distributed PM micelles in 
normal organs were confirmed to eliminate completely within 7 days after injection (Figure 7(a)), 
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indicating no further concern on the serious issues in term of toxicity. It should be also emphasized 
that the 
10
B-enriched PM micelles and the 
10
B-enriched NPM micelles showed no acute toxicity 
even at a dose of 15.6 mg 
10
B/kg, while nido-carborane conjugated liposome showed strong acute 
toxicity within one day even at a dose of 6.0 mg 
10
B/kg [23]. 
Figure 9 shows the changes in the tumor volume of mice bearing colon-26 tumors (n = 5) with 
thermal neutron irradiation for 37 min (1.6–1.8 × 1012 neutrons/cm2) after injecting the 10B-enriched 
PM, NPM micelles, free BSH, or normal saline. The tumor growth in mice treated with the 
10
B-enriched PM micelles without irradiation was similar to that in mice treated with normal saline 
without the irradiation. This indicates that the 
10
B-enriched PM micelles alone and the thermal 
neutron irradiation alone did not suppress the tumor growth. Additionally, no suppression of the 
tumor growth was observed in the mice treated with the 
10
B-enriched NPM micelles with the 
irradiation of the thermal neutrons due to the insufficient concentration of the 
10
B atoms in the 
tumor tissues (3.3 ppm). In sharp contrast, significant suppression of tumor growth was observed in 
the mice treated with the 
10
B-enriched PM micelles with thermal neutron irradiation, after 12 days 
(p < 0.01). Consequently, at day 25, 2 of 5 tumors disappeared completely in the mice treated with 
the 
10
B-enriched PM micelles. Even though the concentration of 
10
B atoms in tumor tissues of the 
mice (14.0 ppm) treated with the 
10
B-enriched PM micelles was almost equal to the concentration in 
mice treated with BSH (12.3 ppm), the 
10
B-enriched PM micelles showed significant therapeutic 
effects after neutron irradiation, compared to those shown by BSH. These data might indicate that 
BSH was extracted from tumor tissues during the irradiation (37 min) due to the short retention time 
of BSH in tumor tissues (< 1 h) as described above (Figure 5(b)). In contrast, the 
10
B atoms were 
able to remain in the tumor tissues of the mice treated with the 
10
B-enriched PM micelles for at least 
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48 h by the EPR effect, consistent with the pharmacokinetics study (Figure 5(b)). These results 
strongly suggest that the retention of 
10
B atoms for longer times in tumor tissues is an important 
factor for achieving beneficial therapeutic effects in BNCT. Figure 10 shows the time course of 
body weight change in mice bearing colon-26 tumor (n = 5) with thermal neutron irradiation for 37 
min after treatment with 
10
B-enriched PM micelles, 
10
B-enriched NPM micelles, free BSH, or 
normal saline. The mice treated with 
10
B-enriched PM micelles, 
10
B-enriched NPM micelles and 
normal saline showed no significant body weight loss compared to the starting weight. On the basis 
of these results, we conclude that the 
10
B-enriched PM micelles are suitable candidates for boron 
carriers in cancer BNCT, and that they exhibit beneficial therapeutic effects without any side-effects. 
Further study on the precise influence of the irradiation against normal organs is currently underway 
in our laboratory. 
 
 
Conclusion 
 
In this study, PM micelles composed of acetal-PEG-b-PLA-MA and VB-carborane were prepared 
to suppress non-specific release of boron compounds into the bloodstream. The PM micelles were 
able to incorporate the high amounts of boron compounds. The release of VB-carborane from the 
PM micelles was completely suppressed in the presence of FBS due to the introduction of covalent 
bonds between the VB-carborane and the PLA core. Additionally, the PM micelles showed 
prolonged blood circulation time and enhanced accumulation of boron species in tumor tissues, in 
compared with the NPM micelles. Both boron species in the PM and NPM micelles were 
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eliminated completely from the body within 7 days after the intravenous injection. It is worth 
noticing that the 
10
B-enriched PM micelles showed remarkable therapeutic efficacy in BNCT; viz, 
selective and non-invasive BNCT was achieved. Therefore, the 
10
B-enriched PM micelles represent 
a promising approach to the creation of boron carriers for cancer BNCT. Additionally, the 
10
B-enriched PM micelles are expected to be accommodated patient treatments since the procedures 
to prepare the micelles require simple processes. 
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1. I would like you to make a slight change to the title, giving it more focus.. Please change it to ' Pharmacokinetics 
of Core-Polymerized, Boron-Conjugated Micelles Designed for Boron Neutron Capture Therapy for Cancer'. 
 
2. You use the word 'novel' in the manuscript. This is not necessary and detracts from the scientific rigour. I would 
like you to delete the word. The same applies to 'new' and similar words, which should not be substituted for 'novel' 
 
3. In the references you should use the accepted abbreviated form for the journal titles - you are inconsistent with 
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    Thank you very much for your comments. According to your comments, we modified the manuscript. 
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Pharmacokinetics of Core-Polymerized, Boron-Conjugated Micelles Designed for Boron Neutron Capture Therapy 
for Cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Answer to reviewer 1: 
 
Thank you very much for your courteous review and kind comments. According to your comments, we revised 
the manuscript as follows (the red colored sentences were revised or newly added sentences in the new 
manuscripts): 
 
Comment 
 
This work is concerned with the synthesis of a new boron compound for BNCT based on delivering a 
carborane molecule by micelles (nanoparticles) constructed by copolymerization (PM micelles). In another recent 
article published by some of the authors (Sumitani S, Oishi M, Nagasaki Y. Carborane confined nanoparticles for 
boron neutron capture therapy: Improved stability, blood circulation time and tumor accumulation. React Funct 
Polym, 2011;71:684-693), a synthesis of a very similar compound (same technique to produce the micelles) but 
cross-linking (CL) the carborane instead of integrating the molecule to the micelle by copolymerization was 
presented. According to their comments in the present manuscript, the CL compound was unable to deliver 
therapeutic amounts of boron to the tumor according to their estimations (yet, no BNCT irradiation was performed 
to investigate the degree of tumor control). Then, in the present manuscript, they chose to prepare the carborane 
co-monomer with only one functional group instead of two as in their previous work with the aim of loading a 
greater amount of boron to the micelles. For comparison, non-polymerized micelles (NPM) containing also a 
carborane molecule were used to test the ability of the PM to preserve their boron load without leaking when 
exposed to serum proteins, concluding that covalent interaction was the cause of the PM stability. In addition, an 
animal model was used in this opportunity to understand its pharmacokinetics and biodistribution and the degree of 
tumor control achieved when irradiated with thermal neutrons. It is of great importance for the future of BNCT to 
have interdisciplinary research groups committed to face sustained efforts in creating new boron compounds and 
delivery strategies. This work is contributory since it integrates several specialties equally important for obtaining a 
suitable compound and therefore deserves to be published. 
 
However, there are still some issues that must be considered when proposing a new boron delivery agent and 
would be of great importance if the authors state them clearly in this work.  
The manuscript is clear and well written and does not demand extensive grammatical corrections, perhaps just 
checking for typing mistakes. 
 
[Q1] The idea of sustained blood circulation is important since it permits the compound to have enough time to 
traverse the barriers that must be crossed to reach the tumor cells; however, it is also a drawback since normal tissues 
could be exposed to high boron radiation doses, unless the compound does not leave the normal vasculature and 
enters the interstitium. The authors should comment on this, perhaps anticipating the need for further investigations 
in terms of boron accumulation in normal tissues that must be protected, e.g., the organs at risk in the future 
treatment. 
 
Answer 
    Thank you for your comment. We understand the importance of the risk at normal organs after the irradiation. 
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Materials 
 
Tetrahydrofuran (THF; Kanto Chemicals Co. Ltd., Tokyo, Japan) was dried over lithium 
aluminum hydride and distilled under nitrogen atmosphere. 3,3-Diethoxy-1-propanol (Aldrich 
Chemical Co. Ltd., Milwaukee, WI) was dried over sodium and distilled under reduced pressure. 
Ethylene oxide (EO; Sumitomo Seika Chemicals Co. Ltd., Hyogo, Japan) was purified by 
distillation over CaH2. D,L-lactide (LA, Wako Pure Chemical Industries, Ltd., Osaka, Japan) was 
purified by sublimation under reduced pressure after recrystallization twice from ethyl acetate. 
Potassium naphthalene was prepared according to a conventional method and the concentration was 
determined by titration. o-Carborane (Wako Pure Chemical Industries),
 10
B-enriched o-carborane 
(Katchem spol. s.r.o., Ltd., Prague, Czech) and butyllithium (BuLi; 1.6 M in n-hexane, Kanto 
Chemicals) were used as received. 4-Vinylbenzyl chloride (kindly provided by Seimi Chemical Co., 
Tokyo, Japan) was purified by passed through silica gel column and distilled under reduced 
pressure. High-resolution mass spectrometry using electrospray ionization mass spectrometry 
(HRMS (ESI+)) was conducted for the synthesized monomers on an Applied Biosystems 
QStar/Pulsar i. 
  
Synthesis of acetal-PEG-b-PLA-MA block copolymer (Scheme S1) 
 
 3,3-Diethoxy-1-propanol (79 L, 0.5 mmol) and THF (15 mL) were added to a round bottom flask 
equipped with a three-way stop-cock under nitrogen atmosphere. To this solution, potassium 
naphthalene solution (0.42 mol/L in THF, 1.2 mL) was added, and the reaction mixture was stirred 
for 30 min at room temperature to obtain of potassium alcholate as an initiator. The condensed EO 
(3.4 mL, 68.1 mmol) was added to the initiator solution via a cooled syringe, and the reaction 
Supplementary Files
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mixture was stirred for 2 days at room temperature. Aliquots of the reaction mixture were sampled 
for SEC measurement to determine the molecular weight of PEG. SEC measurement was carried 
out on an HLC-8020 system (Tosoh, Tokyo, Japan) equipped with an internal refractive index 
detector and a combination of TSKgel G4000HR and TSKgel G3000HR columns (Tosoh, Tokyo, 
Japan), using THF as an eluent (Figure S1). The molecular weight (Mn) and molecular weight 
distribution (Mw/Mn) of PEG were 5,600 and 1.02, respectively, as determined by SEC 
measurements based on the PEG calibration. After the polymerization of EO, a solution of 
D,L-lactide in THF (17.3 mmol, 21.6 mL, 0.8 M) was added, and the reaction mixture was further 
stirred for 2 h at room temperature. Methacrylic anhydride (1.6 mL, 10 mmol) was added to the 
reaction mixture to terminate the reaction and introduce the methacryloyl moiety to the living 
polymer chain end. The reaction mixture was poured into cold 2-propanol (900 mL), followed by 
the centrifuging for 15 min at 5000 rpm at -4 ºC. The recovered polymer was finally freeze-dried 
with benzene to obtain the acetal-PEG-b-PLA-MA polymer as a white powder 
(acetal-PEG-b-PLA-MA: 85.7 % yield). A 
1
H-NMR spectrum of acetal-PEG-b-PLA-MA is shown 
in Figure S2 with assignments, where the peaks of terminal methacryloyl moiety were observed at 
 5.6 and 6.2 ppm along with the peaks of acetal moiety were observed at  4.6 ppm. The segment 
length of PLA was estimated from the 
1
H-NMR spectrum based on the peak integral ratio of the 
methylene protons of PEG (OCH2CH2:  3.5 ppm) and the methine proton of the PLA unit 
(COCH(CH3):  5.2 ppm), assuming the Mn of PEG 5,600. The Mn of PLA segment was 5,100. The 
functionality of methacryloyl and acetal moiety was determined to be 90 and 99 %, respectively, as 
determined by the 
1
H-NMR spectroscopy. SEC Mn = 10,500, Mw/Mn = 1.07; 
1
H-NMR (270 MHz, 
CDCl3): (ppm) 1.18 (t, J = 7.0 Hz, 6H, CH3CH2O-), 1.57 (m, 213H, -COCH(CH3)-), 1.73 (br, 2H, 
acetal-CHCH2CH2O-) 1.76 (br, -C(CH3)=CH2), 3.69 (m, 509H, PEG backbone), 4.64 (t, J = 5.8 Hz, 
1H, acetal-CHCH2-), 5.15 (m, 71H, COCH(CH3)), 5.61 (d, J = 1.3 Hz 1H, -C(CH3)=CH2), 6.20 (d, 
J = 1.1 Hz, 1H, -C(CH3)=CH2).
 
 
Synthesis of natural abundance of 1-(4-vinylbenzyl)-closo-carborane (VB-carborane) (Scheme 
S2) 
 
 o-Carborane (0.38 g, 2.6 mmol) dissolved in THF (20 mL) was introduced in a round bottom flask 
equipped with a three-way stop-cock under nitrogen atmosphere, and the flask was cooled to 0 ºC. 
To this solution, BuLi (1.6 M in hexane) was added dropwise (1.6 mL, 2.6 mmol), and the reaction 
mixture was stirred for 30 min at 0 ºC. The reaction mixture was allowed to warm to room 
temperature, and 4-vinylbenzyl chloride (0.38 mL, 2.6 mmol) was added dropwise. The reaction 
mixture was further stirred for 8 h at room temperature, and the proceeding of the reaction was 
monitored by TLC analysis using straight hexanes (Rf = 0.21). The solvent was subsequently 
removed by rotary evaporation, and the crude product was purified by silica gel column in straight 
hexane to yield the VB-carborane as a white solid (0.13 g, yields; 19.2 %). 
1
H NMR (270 MHz, 
CDCl3) (Figure S3):  (ppm) 1.4-3.5 (br, 11H, carborane), 3.51 (s, 2H, -CH2C(BH)10), 5.30 (dd, J = 
0.8 and 10.8 Hz, 1H, CH2=CHPh), 5.78 (dd, J = 0.8 and 17.6 Hz, 1H, CH2=CHPh), 6.74 (dd, J = 
10.8 and 17.6 Hz, 1H, CH2=CHPh), 7.10 (d, J = 8.2 Hz, 2H, Ph), 7.39 (d, J = 8.2 Hz, 2H, Ph). 
Elemental Analysis: Calcd. C 50.7 %, H 7.74 %. Found C 50.8 %, H 7.70 %. ICP-AES: B Calcd. 
41.5 %, Found 41.4 %. MS (ESI
+
): m/z calcd for C11H20B10 [M
+
]: 260.2568; found: 260.2571. 
 
Synthesis of 
10
B-enriched VB-carborane 
 
 
10
B-enriched o-carborane (0.10 g, 0.69 mmol) dissolved in THF (5.3 mL) was introduced in a 
round bottom flask equipped with a three-way stop-cock under nitrogen atmosphere, and the flask 
was cooled to 0 ºC. To this solution, BuLi (1.6 M in hexane) was added dropwise (0.42 mL, 0.69 
3 
 
mmol), and the reaction mixture was stirred for 30 min at 0 ºC. The reaction mixture was allowed to 
warm to room temperature, and 4-vinylbenzyl chloride (0.11 mL, 0.69 mmol) was added dropwise. 
The reaction mixture was further stirred for 8 h at room temperature, and the proceeding of the 
reaction was monitored by TLC analysis using straight hexanes (Rf = 0.21). The solvent was 
subsequently removed by rotary evaporation, and the crude product was purified by silica gel 
column in straight hexane to yield the 
10
B-enriched VB-carborane as a white solid (65 mg, yields; 
37.4 %). 
1
H NMR (270 MHz, CDCl3):  (ppm) 1.4-3.5 (br, 11H, carborane), 3.51 (s, 2H, 
-CH2C(BH)10), 5.30 (dd, J = 0.8 and 10.8 Hz, 1H, CH2=CHPh), 5.78 (dd, J = 0.8 and 17.6 Hz, 1H, 
CH2=CHPh), 6.70 (dd, J = 10.8 and 17.6 Hz, 1H, CH2=CHPh), 7.10 (d, J = 8.2 Hz, 2H, Ph), 7.39 (d, 
J = 8.2 Hz, 2H, Ph). Elemental Analysis: Calcd. C 52.4 %, H 7.93 %. Found C 53.2 %, H 7.63 %. 
ICP-AES: B Calcd. 39.7 %, Found 40.1 %. 
 
Cell culture 
 
Colon-26 cells derived from mouse colorectal carcinoma cell line were obtained from RIKEN 
BioResource Center. The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) that 
was supplemented with 10% FBS, 100 units mL
-1
 penicillin, and 100 g mL-1 streptomycin at 37 ºC 
in a humidified 5% CO2 atmosphere. 
 
In vitro cytotoxicity 
 
The colon-26 cells were seeded onto 96-well plate at a seeding density of 10
4
 cells/well and 
incubated for 24 h in 100 L DMEM containing 10 % FBS, 100 units/mL penicillin and 100 g/mL 
streptomycin at 37 ºC in humidified 5 % CO2 atmosphere. Then, the culture medium of each well 
was replaced with 90 L of fresh medium, followed by the addition of 10 L sample solutions 
containing various concentration of NPM micelles, PM micelles, or VB-carborane dissolved in 
DMSO. After incubation for 24 h, the metabolic activity of each well was evaluated by WST-8 
assay (Cell Counting Kit-8, Dojindo, Japan) The optical absorbance was measured at 450 nm, using 
an ARVO MX (PerkinElmer, Waltham, MA) and converted to the percentage (cell viability) relative 
to that for mock cells (buffer-treated cells). 
 
Conjugation of tyrosine residues with PM and NPM micelles 
 
To clarify the biodistribution of the micelles, the preparation of 
125
I (radioisotope)-labeled NPM 
and PM micelles were performed. A tyrosine residue (Tyr), as a site of radiolabeling, was 
introduced onto the NPM or PM micelles. An aqueous solution of NPM or PM micelles bearing 
acetal groups (10.0 mL, 2.0 mg/mL) was adjusted to pH 2 using 1.0 M hydrochloric acid, and the 
resulting solution was stirred for 2 h at room temperature to prepare NPM or PM micelles with 
aldehyde groups. Purification was performed with dialysis against a large quantity of water (2.0 L) 
using a pre-swollen semi-permeable membrane (MWCO. 12,000–14,000) for 24 h. The dialysate 
water was exchanged at 2, 5 and 8 h after the beginning of dialysis. To a solution of the NPM or PM 
micelles bearing aldehyde groups (10.0 mL, 1.3 mg/mL, [aldehyde] = ca. 90 M) in 10 mM 
phosphate buffer (pH = 6.5), L-tyrosine (Tyr) hydrazide (10.8 mg, 55 mol) was added, and the 
reaction mixture was stirred at room temperature for 1 h. Next, sodium cyanoborohydride (3.5 mg, 
51 mol) was added as a reducing agent to reduce the unstable hydrazone linkage (C=N-NH-), and 
then the mixture was stirred at room temperature for 24 h. Purification was performed with dialysis 
against a large quantity of water (2.0 L) using a pre-swollen semi-permeable membrane (MWCO: 
12,000–14,000) for 3 days. The dialysate water was exchanged at 2, 5, 8, 24 and 48 h after the 
beginning of dialysis. After purification, 3.0 mL of the solution was freeze-dried to determine the 
4 
 
concentration and the degree of the functionality of the Tyr residue in the 
1
H-NMR spectra. The 
1
H-NMR spectra of the lyophilized NPM or PM micelles in DMSO-d at 80 ºC showed the aromatic 
protons of the Tyr residue, and the degree of functionality of the Tyr residue of the NPM and PM 
micelles was 88 % and 83 %, respectively, as determined from the peak intensity ratio of the 
aromatic protons in Tyr ( 6.8 and 7.2 ppm) to the methine proton in the PLA segment ( 5.2 ppm) 
of the block copolymer. 
 
Radiolabeling of the Tyr-PM and Tyr-NPM micelles 
 
A solution of Na
125
I in 10 mM phosphate-buffered saline (PBS) (15 L, 74 MBq/mL, PerkinElmer, 
Inc., USA) was added to a solution of Tyr-labeled NPM or PM micelles in 10 mM PBS (300 L, 
2.0 mg/mL). A solution of chloramine T in 10 mM PBS (100 L, 2.0 mM) was added to the 
reaction mixture, which was incubated at room temperature for 10 min. Next, the reaction was 
quenched by the addition of a solution of sodium peroxodisulfate in 10 mM PBS (100 L, 40 mM). 
After shaking for a few minutes, the unreacted 
125
I and other chemicals were removed by passing 
the sample through a PD-10 column (GE Healthcare, USA) using PBS as an eluent prior to the 
biodistribution study. The radioactivity of each fraction was measured using a -counter (Aloka, 
Japan) (Figure S5). 
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Scheme S1. Synthesis of acetal-PEG-b-PLA-MA. 
 
 
 
 
 
Scheme S2. Synthesis of 1-(4-vinylbenzyl)-closo-carborane. 
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Figure S1. SEC charts of acetal-PEG (black line) and acetal-PEG-b-PLA-MA (red line). 
 
 
 
 
 
 
 
 
Figure S2. 
1
H-NMR spectrum of acetal-PEG-b-PLA-MA in CDCl3
 
at 25 ºC. 
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Figure S3. 
1
H-NMR spectrum of VB-carborane in CDCl3
 
at 25 ºC. 
 
 
 
 
 
 
Figure S4. The size distribution of the acetal-PEG-b-PLA-MA micelles (black squares), the NPM 
micelles (red circles) and the PM micelles (blue triangles). 
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Figure S5. 
1
H-NMR spectra of lyophilized PM micelles (a) and NPM micelles (b) in chloroform-d. 
 
 
 
 
 
Figure S6. SEC chart changes of the NPM micelles (a) and the PM micelles (b) dependent 
incubation days in 10 mM PBS at 37 ºC. (Column, Superose TM 6 10/300 GL; flow rate, 0.5 
mL/min; eluent, 10 mM phosphate buffer solution, pH 7.4; temperature, 40 ºC). 
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Figure S7. Elution profiles of 
125
I-labeled PM micelles (black squares) and NPM micelles (red 
circles) in purification through gel filtration chromatography (PD-10 column). 
 
 
 
 
 
Figure S8. Cytotoxicity of PM micelles (black squares), NPM micelles (red circles), and 
VB-carborane (blue squares), against colon-26 cells for 24 h. (n=5, mean ± SD). 
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Figure S9. Tissue distribution profiles of the 
125
I-labeled PM micelles (black squares) and the 
125
I-labeled NPM micelles (red circles) in liver (a), spleen (b) and kidney (c) after intravenous 
injection in tumor-bearing mice, determined based on the radioactivity (n = 3, mean ± SD). 
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Figure S10. Tissue distribution of the boron species after intravenous injection of the PM micelles 
(black squares), NPM micelles (red circles) and free BSH (blue triangles) in liver (a), spleen (b) and 
kidney (c) in tumor-bearing mice, determined by ICP-AES (n = 3, mean ± SD). 
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